Literature DB >> 2801316

Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice.

J Björk1, S Kleinau.   

Abstract

The quinoline-3-carboxamide, Linomide, has been shown to possess potent immunomodulatory activity. We have evaluated the effect of Linomide in the type II collagen induced arthritis in mice. Treatment with Linomide (1.25-80 mg/kg/day) from the day of immunization strongly suppressed the arthritic response. On the other hand, initiation of treatment (20-80 mg/kg/day) at the onset of arthritis resulted in an increased severity of the arthritis. These potent and contradictory effects of Linomide, depending on treatment regime, indicates that central immuno-regulatory functions are affected and that this compound may be a useful tool for the understanding of autoimmune mechanisms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2801316     DOI: 10.1007/bf01972810

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  8 in total

1.  Mechanism of action of the new immunomodulator LS2616 on T cell responses.

Authors:  E L Larsson; A Joki; T Stålhandske
Journal:  Int J Immunopharmacol       Date:  1987

2.  Role of T lymphocytes in collagen II induced arthritis in rats.

Authors:  L Klareskog; R Holmdahl; E Larsson; H Wigzell
Journal:  Clin Exp Immunol       Date:  1983-01       Impact factor: 4.330

Review 3.  Collagen arthritis as a relevant model for rheumatoid arthritis.

Authors:  D E Trentham
Journal:  Arthritis Rheum       Date:  1982-08

4.  Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator.

Authors:  T Kalland; G Alm; T Stålhandshe
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

5.  Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice.

Authors:  A Tarkowski; K Gunnarsson; T Stålhandske
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

6.  Immunisation against heterologous type II collagen induces arthritis in mice.

Authors:  J S Courtenay; M J Dallman; A D Dayan; A Martin; B Mosedale
Journal:  Nature       Date:  1980-02-14       Impact factor: 49.962

7.  Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator.

Authors:  A Tarkowski; K Gunnarsson; L A Nilsson; L Lindholm; T Stålhandske
Journal:  Arthritis Rheum       Date:  1986-11

8.  Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat.

Authors:  T Stålhandske; T Kalland
Journal:  Immunopharmacology       Date:  1986-04
  8 in total
  11 in total

1.  Studies on the contribution of c-fos/AP-1 to arthritic joint destruction.

Authors:  S Shiozawa; K Shimizu; K Tanaka; K Hino
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

2.  Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses.

Authors:  J Zhu; X F Bai; G Hedlund; J Björk; M Bakhiet; P H Van Der Meide; H Link
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 3.  S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets.

Authors:  Adam Oesterle; Marion A Hofmann Bowman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-29       Impact factor: 8.311

4.  Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice.

Authors:  Y Fujimori; T Nakamura; K Shimizu; T Yamamuro; K Wanaka; S Okamoto; Y Katsuura
Journal:  Agents Actions       Date:  1993-05

5.  Interleukin-10 mediates the protective effect of Linomide by reducing CXC chemokine production in endotoxin-induced liver injury.

Authors:  Xiang Li; Daniel Klintman; Tohru Sato; Gunnar Hedlund; René Schramm; Bengt Jeppsson; Henrik Thorlacius
Journal:  Br J Pharmacol       Date:  2004-10-18       Impact factor: 8.739

6.  Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug.

Authors:  D J Gross; H Sidi; L Weiss; T Kalland; E Rosenmann; S Slavin
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

7.  Anti-inflammatory properties of zinc protoporphyrin disodium (Zn-PP-2Na).

Authors:  H Nagai; K Kitagaki; K Kuwabara; A Koda
Journal:  Agents Actions       Date:  1992-11

Review 8.  Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.

Authors:  R K Boyapati; A G Rossi; J Satsangi; G-T Ho
Journal:  Mucosal Immunol       Date:  2016-03-02       Impact factor: 7.313

Review 9.  S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease.

Authors:  Alexandru Schiopu; Ovidiu S Cotoi
Journal:  Mediators Inflamm       Date:  2013-12-22       Impact factor: 4.711

10.  Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.

Authors:  Per Björk; Anders Björk; Thomas Vogl; Martin Stenström; David Liberg; Anders Olsson; Johannes Roth; Fredrik Ivars; Tomas Leanderson
Journal:  PLoS Biol       Date:  2009-04-28       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.